Nexvet Biopharma plc Ordinary Shares
NVET
NVET was delisted on the 28th of July, 2017.
18 hedge funds and large institutions have $30.1M invested in Nexvet Biopharma plc Ordinary Shares in 2015 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 4 increasing their positions, 8 reducing their positions, and 2 closing their positions.
50% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 2
6% more funds holding
Funds holding: 17 → 18 (+1)
41% less capital invested
Capital invested by funds: $50.7M → $30.1M (-$20.6M)
50% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 8
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CI
Cowen Inc
New York
|
+$225K |
| 2 |
Bank of America
Charlotte,
North Carolina
|
+$182K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
+$7.59K |
| 4 |
NFG
Next Financial Group
Houston,
Texas
|
+$5.54K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$5.28K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACPU
Arrowgrass Capital Partners (US)
Dover,
Delaware
|
-$1.44M |
| 2 |
Jennison Associates
New York
|
-$369K |
| 3 |
Millennium Management
New York
|
-$153K |
| 4 |
SIM
Spark Investment Management
New York
|
-$123K |
| 5 |
Norges Bank
Oslo,
Norway
|
-$64.4K |
NVET Hedge Fund Activity: Q2 2015 in Review
18 of the 3,712 institutional investors tracked by Wall St. Rank reported a position in Nexvet Biopharma plc Ordinary Shares (NVET) for Q2 2015, worth a combined $30.1M — down 41% from $50.7M a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new NVET positions and 2 closed out — a net gain of 1 holder — while 4 added to existing stakes and 8 trimmed.
The largest buyer was Cowen Inc, opening a new position worth an estimated $225K. The largest seller was Arrowgrass Capital Partners (US), cutting an estimated $1.44M.
- 18 institutional investors held Nexvet Biopharma plc Ordinary Shares (NVET) as of Q2 2015, up from 17 in Q1 2015.
- Funds reported $30.1M of Nexvet Biopharma plc Ordinary Shares stock for Q2 2015, down 41% quarter-over-quarter.
- 3 funds opened new Nexvet Biopharma plc Ordinary Shares positions in Q2 2015 and 2 closed out, a net change of +1 holder.
- The largest Nexvet Biopharma plc Ordinary Shares buyer in Q2 2015 was Cowen Inc, an estimated $225K added.
- The largest Nexvet Biopharma plc Ordinary Shares seller in Q2 2015 was Arrowgrass Capital Partners (US), an estimated $1.44M sold.
Based on aggregated 13F filings for Q2 2015.